Loading...
Please wait, while we are loading the content...
Variant of hepatitis B virus with primary resistance to adefovir.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Schildgen, Oliver Sirma, Hueseyin Funk, Anneke Olotu, Cynthia Wend, Ulrike C. Hartmann, Handledare Elke Helm, Martin Rockstroh, Jürgen K. Willems, Wulf R. Will, H. Gerlich, Wolfram H. |
| Copyright Year | 2006 |
| Abstract | The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, Gilead). All three cases involved a rare HBV variant with a valine at position 233 of the reverse-transcriptase domain instead of isoleucine (rtI233V), as in the wild-type virus. This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir in vitro. |
| Starting Page | 3103 |
| Ending Page | 3112 |
| Page Count | 10 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.gastro-praxis-herne.de/fileadmin/download/New%20England%20Journal%20of%20Medicine.pdf |
| Alternate Webpage(s) | http://hub.hku.hk/bitstream/10722/57524/1/135303.pdf |
| PubMed reference number | 16641397v1 |
| Volume Number | 354 |
| Issue Number | 17 |
| Journal | The New England journal of medicine |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Chemical and Drug Induced Liver Injury Hepatitis B Virus Herpesvirus 1, Cercopithecine In Vitro [Publication Type] Isoleucine Lamivudine SmithKline Beecham Tenofovir Valine adefovir |
| Content Type | Text |
| Resource Type | Article |